Gland Pharma shares today crash to record low. Should you buy post Q2? | Mint
Active Stocks
Tue Feb 27 2024 15:57:55
  1. State Bank Of India share price
  2. 749.70 -1.23%
  1. Tata Steel share price
  2. 144.15 1.09%
  1. Power Grid Corporation Of India share price
  2. 292.50 1.65%
  1. Sun Pharmaceutical Industries share price
  2. 1,579.10 1.42%
  1. ITC share price
  2. 411.15 0.48%
Business News/ Markets / Stock Markets/  Gland Pharma shares today crash to record low. Should you buy post Q2?

Gland Pharma shares today crash to record low. Should you buy post Q2?

Given the near-term top-line growth and margin headwinds, Jefferies has downgraded the stock's rating

Gland Pharma shares plunged to record low Premium
Gland Pharma shares plunged to record low

Shares of Gland Pharma tumbled more than 12% to hit an all-time low of 1,942 apiece on the BSE in Thursday's opening deals after the company reported a 20% decline in consolidated net profit at 241 crore for the second quarter ended September (Q2 FY23), on lower sales and higher expenses. Meanwhile, its revenue and margin also reported a dip from the year-ago quarter.

"Gland Pharma 2QFY23 sales was inline with our estimates but EBITDA/PAT was 13% below. EBITDA margins were depressed on lower gross margin in RoW market, continued high freight costs, increase in employee expense and one-offs. In our view, supply chain challenges will continue to pose growth and margin headwinds in near term with no clarity of resolution," said global brokerage Jefferies.

The brokerage house has downgraded its rating to Hold on Gland Pharma shares with a target price of 2,241 apiece. “Given the near-term top-line growth and margin headwinds, we downgrade the stock to Hold from Buy rating."

Gland Pharma said revenue from its core markets of US, Europe, Canada and Australia grew by 3%, however, India revenue was down 42% while the same for the 'rest of the world' market was also down 3%.

“Gland Pharma’s 2QFY23 results were a mixed bag; while revenue was better than estimate mainly due to a sharp recovery in RoW revenue, margins were lower than our and consensus estimates. The management has also withdrawn FY23 guidance mainly due to cost inflation," said Nirmal Bang in a note while maintaining Buy tag on the pharma stock with a target price of 2,582.

“Sharp improvement in RoW growth was mainly on the back of strong growth in the MENA region as well as improvement in supply of raw materials. The company has also built an additional RM inventory besides securing alternative supplies to mitigate RM supply issues in future. The management expects cost inflation to continue to affect near term margins. Margins are also expected to improve with operational leverage and normalization of cost inflation," the brokerage added.

The views and recommendations made above are those of individual analysts or broking companies, and not of Mint.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates.
More Less
Published: 27 Oct 2022, 09:50 AM IST
Next Story footLogo
Recommended For You

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started
Switch to the Mint app for fast and personalized news - Get App